Cobicistat Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 150 mg
Reference Brands: Tybost (USA/EU)
Category:
Anti Viral
Cobicistat is available in Tablets
and strengths such as 150 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Cobicistat is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Cobicistat can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Cobicistat is a pharmacokinetic enhancer used in combination with antiretroviral medicines for the treatment of human immunodeficiency virus (HIV) infection. Over the past two decades, HIV therapy has advanced significantly, moving from complex multi-dose regimens to simplified once-daily single-tablet combinations. Cobicistat plays an important role in this evolution by boosting the effectiveness of certain antiretroviral drugs. It works by inhibiting enzymes such as cytochrome P450 and transport proteins like P-glycoprotein, which slows the breakdown of partner medications and helps maintain effective drug levels in the body.
Cobicistat serves as an alternative to ritonavir for patients who may not tolerate that booster. It enables the development of convenient fixed-dose combination therapies that may include agents such as tenofovir, emtricitabine, and integrase or protease inhibitors like elvitegravir, atazanavir, or darunavir. Clinical studies have shown that cobicistat-based regimens are generally well tolerated and can achieve high rates of viral suppression in patients receiving HIV treatment.
Cobicistat can cause a mild increase in serum creatinine due to its effect on renal tubular secretion, usually stabilizing after a few weeks of treatment. Overall, it supports modern HIV therapy by helping create effective, simplified, once-daily treatment regimens that improve adherence and long-term disease management.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing